Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Ovid and Angelini partner on treating Angelman syndrome in Europe
  2. Transforming gliobastoma treatment: Imvax closes $112m Series C round
  3. Pandemic logistics: guaranteeing equitable access
  4. Revitope and Junshi collaborate on improved T-cell engager antibodies
  5. From rare diseases to Covid-19: charting the history of Genomics England

Latest Content

Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa’s Second Covid-19 Therapeutic Development Programme

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics’ proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa’s proprietary Endoxifen.

Pandemic logistics: guaranteeing equitable access

The Covid-19 pandemic is a truly global health emergency, and one that will not end unless drugs and vaccines to tackle the deadly viral disease are available to everyone that needs them. This is a lot easier said than done. Allie Nawrat investigates pricing and allocation challenges and solutions that are required to tackle the logistics in ending a worldwide pandemic.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top